Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study

Among patients with relapsed/refractory DLBCL, treatment with brentuximab vedotin plus rituximab and lenalidomide (R2), compared with those who received R2 only, demonstrated statistically significant and clinically meaningful improvements in all key efficacy outcomes with manageable safety, according to results from the ongoing, randomized, double-blind phase 3 ECHELON-3 study—presented during the 2024 ASCO Annual Meeting. At median follow-up of 16.4 months, median OS was 13.8 months in the BV plus R2 group vs 8.5 months in the R2 only group (HR 0.629 [95% CI, 0.445-0.891]; P = 0.0085); OS benefit was consistent across key subgroups.